Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolates

Journal of Clinical Microbiology

Volumn 41, Issue 7, 2003, Pages 3376-3378

  Campo, Rafael E ^a,b   Lichtenberger, Paola N ^a   Rosa, Isabella ^a   Suarez, German ^a   Rivera, Fernando A ^a   Rodriguez, Allan E ^a   Jayaweera, Dushyantha T ^a   Wahlay, Natalie A ^a   Kolber, Michael A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Division of Disease Prevention   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; PREVALENCE; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0038506025     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.7.3376-3378.2003     Document Type: Article

References (18)

1. Bacheler, L., S. Jeffrey, G. Hanna, R. D'Aquila, L. Wallace, K. Logue, B. Cordova, K. Hertogs, B. Larder, R. Buckery, D. Baker, K. Gallagher, H. Scarnati, R. Tritch, and C. Rizzo. 2001. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75:4999-5008.
2. Baxter, J. D., T. C. Merigan, D. N. Wentworth, J. D. Neaton, M. L. Hoover, R. M. W. Hoetelmans, S. C. Piscitelli, W. H. A. Verbiest, and D. L. Mayers. 2002. Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. AIDS 16:1131-1138.
3. Birk, M., V. Svedhem, and A. Sonnerborg. 2001. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS 15:1359-1368.
4. Boden, D., A. Hurley, L. Zhang, Y. Cao, Y. Guo, E. Jones, J. Tsay, J. Ip, C. Farthing, K. Limoli, N. Parkin, and M. Markowitz. 1999. HIV-1 drug resistance in newly infected individuals. JAMA 282:1135-1141.
5. Clevenbergh, P., J. Durant, P. Halfon, P. Delgiudice, V. Mondain, N. Montagne, J. M. Schapiro, C. A. Boucher, and P. Dellamonica. 2000. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: week 48 follow-up. Antivir. Ther. 5:65-70.
6. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelski, et al. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
7. Cozzi Lepri, A., C. A. Sabin, S. Staszewski, K. Hertogs, A. Muller, H. Rabenau, A. N. Phillips, and V. Miller. 2000. Resistance profiles in patients with viral rebound on potent antiretroviral therapy. J. Infect. Dis. 181:1143-1147.
8. Deeks, S. G., T. Wrin, T. Liegler, R. Hoh, M. Hayden, J. D. Barbour, N. S. Hellmann, C. J. Petropoulos, J. M. McCune, M. K. Hellerstein, and R. M. Grant. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480.
9. Garcia-Lerma, J. G., and W. Heneine. 2001. Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing. J. Clin. Virol. 21:197-212.
10. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, et al. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 282:2417-2426.
11. Hooker, D. J., G. Tachedjian, A. E. Solomon, A. D. Gurusinghe, S. Land, C. Birch, J. L. Anderson, B. M. Roy, E. Arnold, and N. J. Deacon. 1996. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J. Virol. 70:8010-8018.
12. Kavlick, M. F., T. Shirasaka, E. Kojima, J. M. Pluda, F. J. Hui, R. Yarchoan, and H. Mitsuya. 1995. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′-dideoxy-3′-thiacytidine. Antivir. Res. 28:133-146.
13. Molla, A., M. Korneyeva, Q. Gao, et al. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
14. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, et al. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
15. Shafer, R. W. 2002. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 15:247-277.
16. Tural, C., L. Ruiz, C. Holtzer, J. Schapiro, P. Viciana, J. Gonzalez, P. Domingo, C. Boucher, C. Rey-Joly, and B. Clotet. 2002. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16:209-218.
17. Verhofstede, C., F. Van Wanzeele, B. Van der Gucht, N. De Cabooter, and J. Plum. 1999. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 13:2541-2546.
18. Weinstock, H., R. Respess, W. Heneine, C. J. Petropoulos, N. S. Hellmann, C.-C. Luo, C.-P. Pau, T. Woods, M. Gwinn, and J. Kaplan. 2000. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J. Infect. Dis. 182:330-333.